Comparative Pharmacology
Head-to-head clinical analysis: DOXAZOSIN MESYLATE versus MINIPRESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXAZOSIN MESYLATE versus MINIPRESS.
DOXAZOSIN MESYLATE vs MINIPRESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors, inhibiting vasoconstriction and reducing peripheral vascular resistance.
Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.
Initial: 1 mg orally 2-3 times daily. Maintenance: 2-5 mg orally 2-3 times daily. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours. This long half-life supports once-daily dosing for hypertension and benign prostatic hyperplasia.
Terminal elimination half-life is 2-3 hours; clinical effect persists longer (up to 24 hours) due to sustained receptor binding.
Approximately 63% of the dose is excreted in feces via biliary elimination, and about 9% is excreted unchanged in urine. The remainder is metabolized, with metabolites excreted in urine and feces.
Primarily hepatic metabolism (90%) with <10% excreted unchanged in urine; 50-60% of metabolites eliminated in bile/feces, 40-50% in urine.
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker